March 6, 2020

Neauvia North America, Inc
Misty Williams
Executive VP Regulatory & Clinical Affairs
8480 Honeycutt Rd
Raleigh, North Carolina 27615

Re: K192813
   Trade/Device Name: Plasma IQ
   Regulation Number: 21 CFR 878.4400
   Regulation Name: Electrosurgical cutting and Coagulation Device and Accessories
   Regulatory Class: Class II
   Product Code: GEI
   Dated: February 3, 2020
   Received: February 4, 2020

Dear Misty Williams:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal
statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/comparison-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.


For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/physical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Long H. Chen -S

Long Chen, Ph.D.
Assistant Director
DHT4A: Division of General Surgery Devices
OHT4: Office of Surgical and Infection Control Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure
510(k) Number (if known)
K192813

Device Name
Plasma IQ

Indications for Use (Describe)
Plasma IQ is used in the removal and destruction of skin lesions and coagulation of tissue.

Type of Use (Select one or both, as applicable)
☐ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

“An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.”
510K Summary – Plasma IQ
As required by 807.92(c)

Date Prepared: March 5, 2020
Sponsor: Neauvia North America

Device Information

Device Name: Plasma IQ
Common Name: Electrosurgical, Cutting & Coagulation & Accessories
Class: II
Product Code: GEI
Regulation: 878.4400
Submission Type: Traditional 510k (Original Submission)

Predicate Information

Primary Predicate: K161134 – Bovie Derm 941, Electrosurgical Generator
Bovie Medical Corporation, Clearwater, FL

Contact Information

Misty Williams
Executive Vice President of Regulatory and Clinical Affairs
Phone: (984) 777-5292
Email: misty@neauvia-us.com

1. Intended Use

PLASMA IQ is used in the removal and destruction of skin lesions and the coagulation of tissue.

2. Device Description

PLASMA IQ utilizes a treatment method called plasma sublimation, which causes controlled skin damage through the generation of an electrical arc. The arc between the electrode tip and the skin is created by a radio frequency generator housed in an electrosurgical unit (handpiece) that ionizes the gas particles in the air. A straight active electrode made of 316L stainless steel is available with the system. The handheld device is cordless and is charged in a docking/charging station prior to use.
3. Performance Testing

The following performance testing was conducted to prove compliance with performance requirements and support substantial equivalence:

<table>
<thead>
<tr>
<th>Test</th>
<th>Objective</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electrical</td>
<td>Compliance with EN 60601-1</td>
<td>Pass</td>
</tr>
<tr>
<td></td>
<td>Compliance with EN 60601-1-2</td>
<td>Pass</td>
</tr>
<tr>
<td>Tissue Testing</td>
<td>Compare thermal spread of devices</td>
<td>Equivalent</td>
</tr>
<tr>
<td>Packaging</td>
<td>Compliance with EN 22248</td>
<td>Pass</td>
</tr>
</tbody>
</table>
4. Substantial Equivalence

<table>
<thead>
<tr>
<th>Trade Name</th>
<th>Submission Device</th>
<th>Predicate Device – Bovie DERM 941 Electrosurgical Generator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturer</td>
<td>Berger &amp; Kraft</td>
<td>Bovie Medical Corporation</td>
</tr>
<tr>
<td>510(k) #</td>
<td>K192813</td>
<td>K161134</td>
</tr>
<tr>
<td>Indications</td>
<td>Intended for the removal and destruction of skin lesions and coagulation of tissue</td>
<td>Intended for the removal and destruction of skin lesions and coagulation of tissue</td>
</tr>
<tr>
<td>Mode of Operation</td>
<td>Plasma Radiofrequency energy ionizes the air creating a Plasma stream</td>
<td>Radiofrequency</td>
</tr>
<tr>
<td>Output</td>
<td>Monopolar</td>
<td>Monopolar</td>
</tr>
<tr>
<td>Power Supply</td>
<td>110-250 VAC 50/60 Hz</td>
<td>100-240 VAC 50-60 Hz</td>
</tr>
<tr>
<td>Frequency</td>
<td>40 kHz</td>
<td>368 kHz</td>
</tr>
<tr>
<td>Max Output Power</td>
<td>5 W</td>
<td>40 W</td>
</tr>
<tr>
<td>Output Impedance</td>
<td>54,000 Ω</td>
<td>200 Ω</td>
</tr>
<tr>
<td>Waveform</td>
<td>![Waveform Image]</td>
<td>![Waveform Image]</td>
</tr>
<tr>
<td>System Components</td>
<td>System consists of a handpiece that incorporates the electrosurgical generator unit, docking station, and an active electrode.</td>
<td>System consists of an electrosurgical generator unit, a handpiece, and dermal tips.</td>
</tr>
<tr>
<td>Electrical Safety Standards</td>
<td>Complies with IEC60601-1, IEC60601-1-2, IEC60601-2-2</td>
<td>Complies with IEC60601-1, IEC60601-2*, and EN60529</td>
</tr>
</tbody>
</table>

*As listed in K170188 510(k) Summary

5. Conclusion

The predicate Bovie Derm 941 and the PLASMA IQ both produce RF energy to remove and destroy skin lesions and coagulate the tissue. The maximum output power of the Plasma IQ device is less than that of the Bovie Derm 941; however, the Plasma IQ and Bovie Derm 941 are substantially equivalent. There are no different questions of safety and effectiveness. Therefore, the subject device and predicate device are
substantially equivalent. Tissue testing, electrical testing (EMC testing) and packaging testing meet the current standards.